These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25445638)

  • 41. HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome.
    Maeda Y; Ugai T; Kondo E; Ikegame K; Murata M; Uchida N; Miyamoto T; Takahashi S; Ohashi K; Nakamae H; Fukuda T; Onizuka M; Eto T; Ota S; Hirokawa M; Ichinohe T; Atsuta Y; Kanda Y; Kanda J;
    Haematologica; 2019 May; 104(5):1055-1061. PubMed ID: 30523056
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.
    Pidala J; Kim J; Alsina M; Ayala E; Betts BC; Fernandez HF; Field T; Jim H; Kharfan-Dabaja MA; Locke FL; Mishra A; Nishihori T; Ochoa-Bayona L; Perez L; Riches M; Anasetti C
    Haematologica; 2015 Jul; 100(7):970-7. PubMed ID: 25840599
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
    McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
    Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
    [TBL] [Abstract][Full Text] [Related]  

  • 45. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.
    Bashey A; Zhang X; Sizemore CA; Manion K; Brown S; Holland HK; Morris LE; Solomon SR
    J Clin Oncol; 2013 Apr; 31(10):1310-6. PubMed ID: 23423745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation.
    Jaskula E; Lange A; Kyrcz-Krzemien S; Markiewicz M; Dzierzak-Mietla M; Jedrzejczak WW; Czajka P; Mordak-Domagala M; Lange J; Gronkowska A; Nowak J; Warzocha K; Hellmann A; Kowalczyk J; Drabko K; Gozdzik J; Mizia S;
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):409-14. PubMed ID: 24345423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
    Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
    van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
    Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation.
    Petersdorf EW; Malkki M; Horowitz MM; Spellman SR; Haagenson MD; Wang T
    Blood; 2013 Mar; 121(10):1896-905. PubMed ID: 23305741
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
    Marsh RA; Bleesing JJ; Chandrakasan S; Jordan MB; Davies SM; Filipovich AH
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1641-5. PubMed ID: 24923536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
    Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between thymic function and allogeneic hematopoietic stem cell transplantation outcome: results of a pediatric study.
    Saglio F; Cena S; Berger M; Quarello P; Boccasavia V; Ferrando F; Pittana L; Bruno B; Fagioli F
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1099-105. PubMed ID: 25708218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
    Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
    Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Second allogeneic hematopoietic cell transplantation for relapse after first allografts.
    Gyurkocza B; Storb R; Chauncey TR; Maloney DG; Storer BE; Sandmaier BM
    Leuk Lymphoma; 2019 Jul; 60(7):1758-1766. PubMed ID: 30668198
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.
    Reshef R; Huffman AP; Gao A; Luskin MR; Frey NV; Gill SI; Hexner EO; Kambayashi T; Loren AW; Luger SM; Mangan JK; Nasta SD; Richman LP; Sell M; Stadtmauer EA; Vonderheide RH; Mick R; Porter DL
    J Clin Oncol; 2015 Jul; 33(21):2392-8. PubMed ID: 26056179
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
    Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.
    Kanakry JA; Gocke CD; Bolaños-Meade J; Gladstone DE; Swinnen LJ; Blackford AL; Fuchs EJ; Huff CA; Borrello I; Matsui WH; Brodsky RA; Rosner GL; Shanbhag S; Luznik L; Jones RJ; Ambinder RF; Kasamon YL
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2115-2122. PubMed ID: 26183076
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research.
    Verneris MR; Lee SJ; Ahn KW; Wang HL; Battiwalla M; Inamoto Y; Fernandez-Vina MA; Gajewski J; Pidala J; Munker R; Aljurf M; Saber W; Spellman S; Koreth J
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1783-9. PubMed ID: 26055300
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of HLA-DPB1 Matching on Outcome of Unrelated Transplant for Hematologic Malignant Diseases: A Systematic Review and Meta-analysis.
    Wang Y; Xu S; Fang P
    Transplant Proc; 2019; 51(6):1982-1989. PubMed ID: 31399180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of non-HLA genomic risk factors in HLA-matched unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia.
    Pearce KF; Lee SJ; Haagenson M; Petersdorf EW; Norden J; Collin MP; Klein JP; Spellman SR; Lowerson SA; Davies S; Dickinson AM
    Haematologica; 2012 Jul; 97(7):1014-9. PubMed ID: 22271889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.